The Science Is Being Held Hostage: Federal Barriers to Cannabis Research Are Costing Lives

Here is what we don’t know about cannabis.

We don’t know the optimal therapeutic dose of THC for chronic pain in adults over 65. We don’t know the long-term cognitive effects of regular low-dose cannabis use in otherwise healthy adults. We don’t know which cannabinoid ratios are most effective for reducing PTSD nightmares, which terpene combinations have meaningful clinical effects, or why some individuals have profound responses to cannabis-based therapies while others experience no benefit.

We don’t know these things because we haven’t adequately studied them. And we haven’t adequately studied them because for fifty years, the federal government has made that study extraordinarily difficult.

The Architecture of Ignorance

Schedule I classification under the Controlled Substances Act requires that any researcher studying cannabis in a clinical context obtain a Schedule I researcher registration from the DEA, use cannabis sourced from a federally approved cultivator (until recently a single facility at the University of Mississippi, with product quality that researchers described as dissimilar to commercially available cannabis), and navigate an approval process that could take years.

A 2023 analysis by the National Academies of Sciences found that the regulatory burden on cannabis research is substantially higher than that for research on Schedule II controlled substances like cocaine or methamphetamine — a disparity that reflects the political history of cannabis policy more than any pharmacological logic.

The practical effects are significant. Clinical trial enrollment has been limited by the difficulty of obtaining federal permission and the reluctance of universities and medical centers to take on the regulatory risk. Researchers who could otherwise attract NIH or FDA funding for cannabis studies have been diverted to more tractable projects. Medical schools have been cautious about building research programs around a Schedule I substance.

The NIH has increased cannabis research funding in recent years — its portfolio now exceeds $200 million annually — but the funding is concentrated in studies of harm, addiction, and negative outcomes rather than therapeutic applications. The imbalance is structural: research dollars follow federal drug policy priorities, and federal drug policy has historically framed cannabis as a problem to be addressed rather than a medicine to be understood.

What We Do Know

Despite the barriers, a body of evidence has accumulated — much of it from international research conducted under less restrictive frameworks.

Israel, which has maintained a government cannabis research program since 2011, has produced some of the most significant clinical work on cannabis and chronic pain, cancer-related nausea, and palliative care applications. Research from Canada, the Netherlands, and the United Kingdom has contributed substantially to understanding cannabinoid pharmacology.

The domestic research that has been conducted — often in state university settings leveraging state-legal cannabis programs — suggests genuine therapeutic promise across multiple indications. Studies on CBD and childhood epilepsy led directly to FDA approval of Epidiolex, the first cannabis-derived pharmaceutical. Research on cannabis and opioid use has repeatedly found that states with medical cannabis laws show reduced opioid mortality — a correlation that has not translated into controlled clinical trials at scale.

The observational and epidemiological evidence is substantial. What’s missing is the controlled clinical trial evidence that would allow physicians to make treatment recommendations based on established efficacy and safety data — the evidence base that FDA approval requires and that any responsible prescribing practice demands.

The Regulatory Reform Opportunity

Two recent developments have created an opening for meaningful change. The HHS research expansion, which followed a 2023 executive action, has streamlined the DEA registration process for researchers and expanded the number of federally approved cannabis cultivators — addressing the supply quality problem that had made much research using federal cannabis questionable.

The rescheduling proposal, if finalized, would reclassify cannabis as Schedule III. While that change would not eliminate all research barriers — Schedule III substances still require DEA registration and approval — it would reduce the regulatory burden, normalize federal funding for therapeutic research, and signal a policy posture more consistent with medical inquiry.

“We’re not starting from zero,” said one NIH-funded researcher studying cannabis and anxiety disorders. “But we’re starting from further behind than we should be. Every year of unnecessary restriction is a year of science we can’t get back.”

The Patient Cost

The abstract policy discussion has concrete human consequences. Patients with conditions for which cannabis shows preliminary evidence — epilepsy, chronic pain, PTSD, multiple sclerosis, Crohn’s disease — are currently making treatment decisions with their healthcare providers based on insufficient evidence.

Some of those patients are using cannabis anyway, guided by anecdote, dispensary staff recommendations, or online communities where information quality varies dramatically. A robust research base would give physicians actual evidence to work with — information about what dose, what formulation, what timing, and what patient characteristics predict good outcomes.

Instead, the system has made that research maximally difficult, for maximally bureaucratic reasons, while tens of millions of Americans use cannabis for health-related purposes.

The rescheduling conversation and the banking conversation consume most of the political oxygen in cannabis policy. The research conversation — quieter, more technical, with longer time horizons — may ultimately matter more.